Trial Profile
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cycloserine (Primary)
- Indications Bipolar disorders; Schizophrenia
- Focus Pharmacodynamics; Therapeutic Use
- 18 Sep 2017 Status changed from recruiting to completed.
- 29 Jan 2017 Planned End Date changed from 1 May 2017 to 1 Jul 2017.
- 29 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jul 2017.